OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study

Survivin (BIRC5) is broadly overexpressed in human cancers but, as a self-antigen, is subject to immune tolerance that limits spontaneous antitumour immunity. OVM-200 is a recombinant overlapping peptide vaccine spanning full-length survivin, with cathepsin S-cleavable linker sequences inserted between adjacent peptides to enhance antigen processing and presentation. OVM-200-100 was a multicentre, open-label phase 1 study conducted at 4 UK sites. The pooled 2,000-g cohort comprised 27 patients with advanced non-small cell lung, ovarian or prostate cancer, including 24 patients from phase 1b an

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.